Neurocrine Biosciences (NBIX) EPS (Basic) (QoQ) (2010 - 2026)
Neurocrine Biosciences (NBIX) EPS (Basic) (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -27.40% |
| Mar 31, 2026 | 27.48% |
| Dec 31, 2025 | -26.71% |
| Sep 30, 2025 | 94.10% |
| Jun 30, 2025 | 1,270.38% |
| Mar 31, 2025 | -92.28% |
| Dec 31, 2024 | -20.02% |
| Sep 30, 2024 | 99.10% |
| Jun 30, 2024 | 48.28% |
| Mar 31, 2024 | -71.23% |
| Dec 31, 2023 | 78.10% |
| Sep 30, 2023 | -13.25% |
| Jun 30, 2023 | 224.03% |
| Mar 31, 2023 | -184.92% |
| Dec 31, 2022 | 29.93% |
| Sep 30, 2022 | 504.48% |
| Jun 30, 2022 | -221.20% |
| Mar 31, 2022 | 289.01% |
| Dec 31, 2021 | -132.48% |
| Sep 30, 2021 | -46.86% |